Neuropsychiatric Drug Development
•93 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (93)
%
| Company | Market Cap | Price |
|---|---|---|
|
Kisunla is a neuroscience/Alzheimer's program; aligns with Neuropsychiatric Drug Development.
|
$789.93B |
$833.49
-2.86%
|
|
Neuropsychiatric drug development evidenced by CAPLYTA in adjunctive MDD, representing CNS/psychiatric therapeutics.
|
$458.89B |
$190.72
-0.67%
|
|
Vraylar is a neuropsychiatric CNS drug, aligning with neuropsychiatric drug development tagging.
|
$431.71B |
$236.56
-1.80%
|
|
Cobenfy's neuropsychiatric development (schizophrenia, Alzheimer's-related studies) fits Neuropsychiatric Drug Development.
|
$89.46B |
$43.96
-1.83%
|
|
Oveporexton is a first-in-class CNS agent for narcolepsy, fitting neuropsychiatric drug development.
|
$43.58B |
$27.33
-2.62%
|
|
Oreporexton/Orexin-based therapies for NT1 fall under Neuropsychiatric Drug Development.
|
$43.47B |
$13.71
-1.01%
|
|
AUSTEDO is a neuropsychiatric drug; Teva’s pipeline includes neuropsychiatric candidates.
|
$22.95B |
$20.01
+0.05%
|
|
Company focus on CNS/neuropsychiatric disorders (e.g., MDD, schizophrenia) and a pipeline aimed at multi-blockbuster neuroscience therapies.
|
$14.51B |
$146.95
+0.38%
|
|
Phase 3 exploration of EFFEXOR GAD in Japan indicates neuropsychiatric drug development activity.
|
$11.17B |
$9.52
-0.42%
|
|
Pipeline includes neurological and neurodevelopmental programs (Angelman syndrome, Alexander disease, CNS delivery) aligning with neuropsychiatric/drug-development themes.
|
$11.14B |
$69.97
-0.04%
|
|
Regencell's core focus is the development of neuropsychiatric therapeutics (ADHD/ASD) using proprietary formulations, clearly fitting neuropsychiatric drug development.
|
$8.31B |
$16.81
-8.54%
|
|
Jazz's sleep disorder and CNS products (e.g., Xywav) place it in neuropsychiatric drug development.
|
$7.99B |
$129.59
-0.16%
|
|
Axsome's focus is on CNS/neurological and psychiatric disorders, i.e., neuropsychiatric drug development.
|
$5.99B |
$121.71
-0.66%
|
|
Core focus on CNS/neuropsychiatric therapeutics and related research programs (schizophrenia, narcolepsy, hypersomnia).
|
$5.15B |
$31.21
-0.54%
|
|
CNS/neurology pipeline (e.g., Huntington's) supports neuropsychiatric drug development.
|
$4.89B |
$35.41
-1.64%
|
|
MRM-3379 is a PDE4D inhibitor being developed for Fragile X Syndrome, placing the company in neuropsychiatric/neurology drug development.
|
$3.64B |
$73.57
-0.65%
|
|
ACADIA develops CNS/neuropsychiatric therapeutics, including NUPLAZID for PDP and DAYBUE for Rett syndrome, positioning it in neuropsychiatric drug development.
|
$3.52B |
$21.05
-0.94%
|
|
Neuropsychiatric drug development focus (e.g., KarXT) aligns with the neuropsychiatric therapeutics theme.
|
$3.43B |
$31.62
+0.86%
|
|
Indivior's focus on opioid use disorder and CNS/psychiatric therapeutics aligns with Neuropsychiatric Drug Development.
|
$3.28B |
$23.78
-1.53%
|
|
Neuropsychiatric/drug-development orientation illustrated by the CREXONT Parkinson's asset and CNS/MCI focus.
|
$3.12B |
$9.97
-3.11%
|
|
The company is running Phase 3 programs in Major Depressive Disorder and Bipolar Depression, indicating neuropsychiatric drug development focus.
|
$3.04B |
$39.64
-4.34%
|
|
Orexin-based therapies are aimed at neuropsychiatric conditions such as narcolepsy and sleep disorders.
|
$2.98B |
$22.31
-2.75%
|
|
Core CNS neuropsychiatric drug development focus aligns with Qelbree, GOCOVRI, ONAPGO, and ZURZUVAE and the pipeline assets.
|
$2.74B |
$49.00
-0.79%
|
|
Neuropsychiatric drug development encompassing OCD and MDD CNS indications.
|
$1.61B |
$15.80
-9.97%
|
|
The company focuses on neuropsychiatric and sleep/wake disorders (narcolepsy, Fragile X–related neurobehavioral conditions, rare CNS diseases), aligning with Neuropsychiatric Drug Development.
|
$1.52B |
$26.54
-1.19%
|
|
Company is developing CNS/sleep-disorder therapeutics (narcolepsy, Idiopathic Hypersomnia).
|
$1.51B |
$15.49
-0.61%
|
|
HD is a CNS/neurodegenerative disorder; WVE-003 aims to modify disease progression, fitting Neuropsychiatric Drug Development.
|
$1.17B |
$7.60
-8.21%
|
|
Jornay PM is a neuropsychiatric drug (ADHD), aligning with Neuropsychiatric Drug Development.
|
$1.11B |
$34.22
-0.55%
|
|
Neuropsychiatric drug development is a core focus, including rapid-acting CNS/psychiatric therapies.
|
$1.05B |
$5.23
+1.16%
|
|
Rapport Therapeutics develops targeted small-molecule therapies for neurological and psychiatric disorders, fitting Neuropsychiatric Drug Development.
|
$967.19M |
$26.50
-1.08%
|
|
MM120 and MM402 programs target CNS/psychiatric conditions, fitting Neuropsychiatric Drug Development.
|
$892.28M |
$11.81
-5.75%
|
|
Praxis' CNS/neurology focus spans epilepsy, essential tremor, and movement disorders, aligning with neuropsychiatric drug development themes.
|
$859.98M |
$47.67
-1.37%
|
|
Schizophrenia program places the company in Neuropsychiatric Drug Development.
|
$791.40M |
$9.27
-1.80%
|
|
Neuropsychiatric Drug Development captures TBPH's lead neurology program and CNS-focused therapeutic development.
|
$699.52M |
$13.99
-3.12%
|
|
Company is developing neuropsychiatric drug therapeutics targeting CNS/psychiatric indications (depression, TRD, bipolar disorder, postpartum depression).
|
$655.03M |
$12.59
-4.48%
|
|
Neurodegenerative/CNS program: AAV-GAD for Parkinson's represents a CNS-focused therapeutic.
|
$630.06M |
$7.84
-11.11%
|
|
KP1077 targets CNS/neuropsychiatric indications (IH and narcolepsy), placing Zevra in Neuropsychiatric Drug Development.
|
$602.02M |
$11.01
+0.18%
|
|
The company is focused on neuropsychiatric drug development, specifically psychedelic-based therapeutics for mental health conditions.
|
$581.95M |
$6.22
-4.31%
|
|
ARV-102 is a brain-penetrant LRRK2 degrader for Parkinson's, placing the company in CNS/neurodegenerative therapeutic development.
|
$548.90M |
$7.52
-2.59%
|
|
PureTech benefits from neuropsychiatric drug development exposure via KarXT royalties and related assets, aligning with Neuropsychiatric Drug Development.
|
$464.27M |
$18.00
|
|
CNS-focused neurodegenerative/neurology drug development category.
|
$375.71M |
$8.05
|
|
Parkinson's disease immunotherapy and other CNS programs place AC Immune in the Neuropsychiatric Drug Development space.
|
$354.43M |
$3.55
+0.28%
|
|
Pipeline includes Huntington's disease (HD) and DM1 with CNS-related and neurological considerations, aligning with Neuropsychiatric Drug Development.
|
$346.86M |
$6.11
-4.08%
|
|
Fanapt and bipolar I disorder expansion, plus a broader psychiatry-focused pipeline, align with Neuropsychiatric Drug Development.
|
$312.94M |
$5.31
-3.80%
|
|
Core business focus on neuropsychiatric drug development, including navacaprant and NMRA-511 with a CNS/neurodegenerative pipeline.
|
$305.70M |
$1.89
-3.08%
|
|
Neuropsychiatric Drug Development reflects the company's focus on CNS/neurodegenerative indications such as FTD, AD, and PD.
|
$301.98M |
$3.02
-5.48%
|
|
CNS/neuropsychiatric drug development focus including RRMS and MDD positions Contineum in the Neuropsychiatric Drug Development theme.
|
$293.64M |
$11.16
-1.63%
|
|
Bright Minds Biosciences develops CNS/psychiatric therapeutics (5-HT receptor agonists) and is advancing BMB-101 in Phase 2, aligning with Neuropsychiatric Drug Development.
|
$282.52M |
$63.29
+2.58%
|
|
A CNS-penetrant TYK2 inhibitor (A-005) supports neuroinflammatory indications such as MS, linking to neuropsychiatric drug development.
|
$224.15M |
$4.29
+4.25%
|
|
Neuropsychiatric Drug Development captures CNS/psychiatric therapeutic focus implicit in neurodegenerative disease programs.
|
$210.30M |
$2.04
-5.56%
|
|
Clinical focus on neurological indications (pain, prion disease) aligns with Neuropsychiatric Drug Development.
|
$156.76M |
$0.67
-10.35%
|
|
Fibromyalgia is a CNS/neurological and neuropsychiatric indication, aligning with neuropsychiatric drug development themes.
|
$155.21M |
$21.19
-4.46%
|
|
The company focuses on neuropsychiatric drug development for disorders such as MDD, bipolar depression, TRD, and schizophrenia.
|
$152.69M |
$5.64
-6.47%
|
|
The company is focusing on CNS disorders, including epilepsy, aligning with neuropsychiatric drug development themes.
|
$144.44M |
$2.90
-2.84%
|
|
Risvodetinib (IkT-148009) is a CNS/neurology program (Parkinson's disease/MSA) that has been outlicensed, indicating neurology-focused assets.
|
$120.43M |
$1.62
|
|
Core focus on neuropsychiatric drug development using a non-systemic intranasal pherine platform for CNS disorders (e.g., fasedienol for SAD).
|
$117.51M |
$4.03
-4.73%
|
|
Company focuses on neurodegenerative CNS drug development, aligning with Neuropsychiatric Drug Development.
|
$112.46M |
$7.02
-7.99%
|
|
Lead programs target ALS and FTD, placing COYA in the neurodegenerative CNS drug development space.
|
$101.52M |
$6.07
-3.04%
|
|
Cannabinoid receptor–targeted CNS/s neuropsychiatric–oriented drug development aligns with neuropsychiatric drug development as a general category.
|
$95.32M |
$2.32
+2.20%
|
|
Company focuses on CNS/neurodegenerative therapeutics, fitting the Neuropsychiatric Drug Development theme.
|
$85.62M |
$0.01
|
|
Pipeline focuses on CNS/neurodegenerative conditions (Alzheimer's disease and dementia with Lewy bodies), aligning with 'Neuropsychiatric Drug Development'.
|
$83.69M |
$1.35
+1.50%
|
|
Sympazan is a CNS/neurology-focused therapy (neuropsychiatric area) used for seizure management, aligning with Neuropsychiatric Drug Development.
|
$79.98M |
$0.83
-4.47%
|
|
Neflamapimod targets CNS/degenerative conditions (DLB/FTD), aligning with 'Neuropsychiatric Drug Development' investable theme.
|
$70.93M |
$8.15
-5.12%
|
|
Sepranolone targets compulsivity disorders (Tourette Syndrome, Prader-Willi Syndrome), aligning with Neuropsychiatric Drug Development.
|
$67.71M |
$2.04
-8.93%
|
|
Pipeline focus includes CNS/neurodegenerative indications (ALS, MS), aligning with 'Neuropsychiatric Drug Development'.
|
$62.78M |
$1.28
+3.23%
|
|
Lead PD program aligns with Neuropsychiatric Drug Development within the CNS/neurodegenerative space.
|
$56.75M |
$2.23
+16.15%
|
|
NRx's pipeline focuses on CNS/neuropsychiatric indications (suicidal depression, bipolar disorder), fitting Neuropsychiatric Drug Development.
|
$54.81M |
$3.17
-11.70%
|
|
Clene is focused on neurological diseases (ALS/MS), aligning with neurodegenerative/neuroscience therapeutic development.
|
$54.35M |
$6.05
-1.14%
|
|
Focus on neuropsychiatric/neurotherapeutic development ( Parkinson's-related programs SER-252/SER-214 and SER-270).
|
$52.93M |
$5.31
-0.38%
|
|
ABVC's ABV-1504 is a Major Depressive Disorder program, indicating CNS/Neuropsychiatric drug development.
|
$50.99M |
$3.04
-7.03%
|
|
Pipeline targets neuroinflammation and CNS disorders (Parkinson's and cognitive impairment), fitting Neuropsychiatric Drug Development.
|
$50.65M |
$1.53
-3.77%
|
|
TRD program for peripheral inflammation and anhedonia indicates neuropsychiatric drug development.
|
$48.97M |
$2.08
-1.18%
|
|
ATH434 targets CNS/neurodegenerative disease pathways, aligning with neuropsychiatric drug development.
|
$45.65M |
$4.29
-1.38%
|
|
IGC’s programs target agitation in Alzheimer’s dementia, fitting Neuropsychiatric Drug Development.
|
$33.48M |
$0.40
-4.29%
|
|
Pipeline targets neuropathic pain and anxiety/cognition-related indications, placing it in Neuropsychiatric Drug Development.
|
$21.32M |
$1.26
-6.67%
|
|
Direct focus on neuropsychiatric CNS therapeutics (roluperidone) for schizophrenia negative symptoms.
|
$16.43M |
$2.35
-2.89%
|
|
Company develops neuropsychiatric therapeutics (BXCL501) for agitation, a CNS/psychiatric drug development program.
|
$15.32M |
$2.53
-3.80%
|
|
Athira's lead program ATH-1105 targets ALS, a CNS neurodegenerative condition, aligning with neuropsychiatric/CNS drug development themes.
|
$14.84M |
$3.80
-3.06%
|
|
LPCN 1154 targets postpartum depression, a CNS/neuropsychiatric indication, aligning with Neuropsychiatric Drug Development.
|
$14.61M |
$2.73
-1.80%
|
|
AYTU's ADHD and pediatric neuropsychiatric portfolio places it in the neuropsychiatric drug development / CNS category.
|
$14.56M |
$2.36
-7.45%
|
|
Company is pivoting to an individualized therapy for Treatment Resistant Depression, a neuropsychiatric drug development focus.
|
$7.48M |
$2.33
-5.67%
|
|
Addex's strategy and assets focus on neuropsychiatric drug development (e.g., schizophrenia via Neurosterix M4 PAM program, Dipraglurant for brain injury), fitting Neuropsychiatric Drug Development.
|
$7.43M |
$9.44
+7.49%
|
|
BETRF's pipeline includes BETR-001 and BETR-002, non-hallucinogenic neuroplastogens targeting mental health and anxiety-related disorders.
|
$7.04M |
$0.04
-6.38%
|
|
ALZN targets neuropsychiatric conditions (BD, MDD, PTSD) through novel therapies, aligning with Neuropsychiatric Drug Development.
|
$6.31M |
$2.18
-5.63%
|
|
Company cites CNS disorders as a focus, aligning with Neuropsychiatric Drug Development.
|
$5.58M |
$0.75
-3.55%
|
|
Company operates in neuropsychiatric drug development within the psychedelic medicine space.
|
$3.70M |
$0.93
-5.00%
|
|
BioVie's pipeline targets CNS disorders including Alzheimer's and Parkinson's, fitting Neuropsychiatric Drug Development as a CNS/neurodegenerative focus.
|
$3.40M |
$1.83
-8.50%
|
|
ADIL's lead product targets CNS/neuropsychiatric conditions (AUD), placing it in neuropsychiatric drug development.
|
$3.15M |
$0.39
-3.34%
|
|
BICX104 represents a long-acting drug-delivery candidate for opioid and stimulant use disorders, fitting Neuropsychiatric Drug Development.
|
$2.98M |
$0.45
|
|
PTSD and CNS-related neuropsychiatric indications position the company in Neuropsychiatric Drug Development.
|
$2.52M |
$0.56
-16.31%
|
|
Core CNS/psychiatric drug development pipeline (narcolepsy, ADHD, sleep disorders) aligns with Neuropsychiatric Drug Development.
|
$1.73M |
$1.76
-4.35%
|
|
EB-3.00 (EVM301 series) is a lead neuropsychiatric drug development program advancing toward clinical trials.
|
$1.71M |
$0.68
-1.76%
|
|
MS-related therapeutic development aligns with neuro/immunology drug research.
|
$229298 |
$0.00
|
Loading industry metrics...
Loading comparison data...
